{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:22:00Z","timestamp":1783606920314,"version":"3.55.0"},"reference-count":59,"publisher":"Bioscientifica","issue":"6","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy with limited therapeutic options in advanced disease. While selective RET inhibitors have expanded systemic treatment strategies, disease progression frequently occurs over time. Antibody\u2013drug conjugates (ADCs) have shown efficacy in the treatment of solid tumors but require suitable cell-surface targets, which have not yet been systemically characterized in MTC. This study aimed to identify therapeutically relevant surface antigens in MTC using immunohistochemical profiling. In this retrospective exploratory study, tumor specimens of 41 patients with histologically confirmed MTC were analyzed. Formalin-fixed paraffin-embedded tissues from primary tumors were subjected to immunohistochemical staining for six therapeutically relevant cell-surface antigens. Surface expression was assessed and categorized as strong, weak, or absent. Statistical analyses were conducted using descriptive statistics and Fisher\u2019s exact test. The study included 41 patients with MTC, representing different tumor stages and clinicopathological characteristics with lymph node involvement in 45%. B7-H3 showed membranous expression in 91% of the included cases with strong expression in 82%, which was consistent across tumor stages and clinical subgroups. In contrast, no expression was detected for Nectin-4, Trop-2, c-Met, PD-L2, and Claudin 18.2 in any evaluable samples. B7-H3 was identified as the only consistently and strongly expressed surface antigen in a clinically heterogeneous MTC cohort. These findings identify B7-H3 as a potential therapeutic opportunity for advanced MTC and underscore the limited number of targetable surface antigens in this disease.<\/jats:p>","DOI":"10.1530\/erc-26-0241","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:40:30Z","timestamp":1780396830000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-2767","authenticated-orcid":true,"given":"Teresa","family":"Binter","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Tomasich","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-0206","authenticated-orcid":true,"given":"Philipp","family":"Melhorn","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mazal","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Riss","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Scheuba","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bergmeister-Berghoff","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-5802","authenticated-orcid":true,"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026070909475286200_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2026070909475286200_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070909475286200_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/thy.2023.0279","article-title":"Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study","volume":"34","author":"Xu","year":"2024","journal-title":"Thyroid"},{"key":"2026070909475286200_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000445978","article-title":"Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma","volume":"90","author":"Heilmann","year":"2016","journal-title":"Oncology"},{"key":"2026070909475286200_bib5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"2026070909475286200_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","article-title":"Medullary thyroid carcinoma","volume":"22","author":"Pacini","year":"2010","journal-title":"Clin Oncol"},{"key":"2026070909475286200_bib7","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. food and drug administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026070909475286200_bib8","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070909475286200_bib10","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070909475286200_bib11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2026070909475286200_bib12","article-title":"The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: a systematic review","volume":"192","author":"Filis","year":"2023","journal-title":"Crit Rev Oncolhematol"},{"key":"2026070909475286200_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2026070909475286200_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026070909475286200_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates \u2013 an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br J Cancer"},{"key":"2026070909475286200_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210019","article-title":"CD276 as a candidate target for immunotherapy in medullary thyroid cancer","volume":"24","author":"Hi\u0144cza-Nowak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026070909475286200_bib17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3390\/genes12101534","article-title":"Immune profiling of medullary thyroid cancer \u2013 an opportunity for immunotherapy","volume":"12","author":"Hi\u0144cza-Nowak","year":"2021","journal-title":"Genes"},{"key":"2026070909475286200_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1089\/thy.2019.0604","article-title":"Comprehensive immune profiling of medullary thyroid cancer","volume":"30","author":"Pozdeyev","year":"2020","journal-title":"Thyroid"},{"key":"2026070909475286200_bib19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"2026070909475286200_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett"},{"key":"2026070909475286200_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"key":"2026070909475286200_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100165","article-title":"Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2\u2013targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumors","volume":"53","author":"Cheng","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"2026070909475286200_bib23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met antibody\u2013drug conjugate that targets both MET\u2013amplified and c-Met\u2013overexpressing tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026070909475286200_bib24","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2\u2013targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"2026070909475286200_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody\u2013drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026070909475286200_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41698-025-01011-7","article-title":"Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment","volume":"9","author":"Marchesi","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026070909475286200_bib27","article-title":"The human protein atlas. n.d","author":"Anonymous"},{"key":"2026070909475286200_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"2026070909475286200_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00292-025-01441-x","article-title":"[Trop-2 expression in solid tumors: expanded protein diagnostics within the molecular tumor board]","volume":"46","author":"Dopfer","year":"2025","journal-title":"For Pathol"},{"key":"2026070909475286200_bib30","first-page":"785","article-title":"Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry \u2013 what do we know?","volume":"40","author":"Sanders","year":"2024","journal-title":"Histol Histopathol"},{"key":"2026070909475286200_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jcp-2023-209202","article-title":"c-Met immunohistochemistry as reflex test at diagnosis for non-small cell lung cancer: a real-world experience from a monocentric case series","volume":"78","author":"Bontoux","year":"2025","journal-title":"J Clin Pathol"},{"key":"2026070909475286200_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a new biomarker in gastric cancer \u2013 what should we know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers"},{"key":"2026070909475286200_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100589","article-title":"Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol"},{"key":"2026070909475286200_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12894-022-01044-1","article-title":"Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer","volume":"22","author":"Mahmoud","year":"2022","journal-title":"BMC Urol"},{"key":"2026070909475286200_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2026.106078","article-title":"Scoring reliability of c-Met immunohistochemical assays in lung adenocarcinoma","volume":"106","author":"Zhou","year":"2026","journal-title":"Lab Investig"},{"key":"2026070909475286200_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41379-021-00917-4","article-title":"Standardization of PD-L1 immunohistochemistry","volume":"35","author":"Martinez-Morilla","year":"2022","journal-title":"Mod Pathol"},{"key":"2026070909475286200_bib37","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026070909475286200_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"key":"2026070909475286200_bib39","article-title":"Pembrolizumab in recurrent or metastatic medullary thyroid cancer","volume":"31","author":"Rivero","year":"2025","journal-title":"Oncol"},{"key":"2026070909475286200_bib40","first-page":"134","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Jr","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib41","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"2026070909475286200_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026070909475286200_bib43","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.7150\/ijbs.85813","article-title":"B7-H3 in brain malignancies: immunology and immunotherapy","volume":"19","author":"Guo","year":"2023","journal-title":"Int J Biol Sci"},{"key":"2026070909475286200_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.600238","article-title":"The expression of three negative co-stimulatory B7 family molecules in small cell lung cancer and their effect on prognosis","volume":"11","author":"Qiu","year":"2021","journal-title":"Front Oncol"},{"key":"2026070909475286200_bib45","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1158\/1078-0432.CCR-24-3981","article-title":"Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes","volume":"31","author":"Gay","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026070909475286200_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026070909475286200_bib47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat Med"},{"key":"2026070909475286200_bib48","doi-asserted-by":"crossref","first-page":"TPS5125","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5125","article-title":"A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: the help elucidate and attack longitudinally (HEAT) prostate cancer randomized study","volume":"42","author":"Shenderov","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib49","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/2767-9764.CRC-25-0293","article-title":"A phase I, open-label, dose escalation study of enoblituzumab in children and young adults with B7-H3\u2013Expressing relapsed or refractory solid tumors","volume":"5","author":"DeSantes","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026070909475286200_bib50","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1200\/JCO.2024.42.16_suppl.8093","article-title":"ARTEMIS-001: data from a phase 1a\/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026070909475286200_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188783","article-title":"To kill a cancer: targeting the immune inhibitory checkpoint molecule, B7-H3","volume":"1877","author":"Kanchan","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026070909475286200_bib53","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/j.annonc.2023.09.1876","article-title":"690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: updated clinical and biomarker results from a phase I\/II study","volume":"34","author":"Patel","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070909475286200_bib54","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","article-title":"Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: dose expansion results","volume":"41","author":"Carneiro","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib55","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2024.42.16_suppl.3012","article-title":"Results of a phase 1\/2 study of MHB088C: a novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib56","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"2026070909475286200_bib57","doi-asserted-by":"crossref","first-page":"TPS5099","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5099","article-title":"Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer","volume":"36","author":"Shenderov","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070909475286200_bib58","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1080\/14796694.2025.2565995","article-title":"IDeate-Lung02: a phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","volume":"21","author":"Owonikoko","year":"2025","journal-title":"Futur Oncol"},{"key":"2026070909475286200_bib59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13000-024-01504-2","article-title":"B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma","volume":"19","author":"Song","year":"2024","journal-title":"Diagn Pathol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/6\/ERC-26-0241.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/6\/ERC-26-0241.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0241\/520252\/erc-26-0241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0241\/520252\/erc-26-0241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:48:04Z","timestamp":1783604884000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/6\/e260241\/77623\/B7-H3-CD276-as-a-candidate-therapeutic-target-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0241","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"e260241"}}